New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
08:12 EDTHSP, DANOYHospira to obtain financial benefits from possible Danone deal, says Wells Fargo
After multiple media sources reported that Hospira (HSP) is in talks to buy Danone's (DANOY) medical nutrition business in a potential tax inversion deal, Wells Fargo estimates that the deal could be 9%-12% accretive to Hospira's EPS in 2015-2017 if it's an all-stock deal and 20%-22% accretive if it's a 50%/50% cash and stock deal. The firm The firm estimates that Hospira's tax bill would be cut to 21% in 2015 and 19% afterwards, from its current forecast of 24%-26% during those years. The firm thinks the strategic rationale for the deal from Hospira's perspective, however, is less clear. It keeps a Market Perform rating on the stock.
News For HSP;DANOY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
09:52 EDTHSPAlliance for Health Reform holds a webcast on biosimilars
"Biosimilars in the U.S.: Current & Emerging Issues" provides essential background on the U.S. and international markets for reference biologics and biosimilars, outline current policy and regulatory issues, and describe implications for the future. Speakers include Chief Scientific Officer Ramachandra from Hospira, Executive Director Eich from Amgen on the briefing being held on May 20 at 12 pm. Webcast Link
May 14, 2015
12:29 EDTHSPPfizer receives 'second request' from FTC regarding potential Hospira merger
Subscribe for More Information
May 13, 2015
19:17 EDTHSPHospira and FDA detect security vulnerabilities in infusion pumps
Subscribe for More Information
13:43 EDTHSPHospira shareholders approve merger with Pfizer
Hospira (HSP) announced that Hospira shareholders voted in favor of the proposal to adopt the merger agreement with Pfizer (PFE) at a special meeting of stockholders held May 13 in Denver, Colorado. On February 5, Hospira and Pfizer announced they had entered into a merger agreement under which Pfizer will acquire Hospira for $90 per share in cash for a total enterprise value of approximately $17B. The merger is subject to customary closing conditions, one of which was approval of the merger by Hospira's shareholders. Additional closing conditions to be met include obtaining regulatory approvals in several jurisdictions. Hospira and Pfizer continue to expect the merger to close in the second half of 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use